treatment
desper
need
lower
hospit
case
fatal
rate
sar
infect
order
meaning
impact
pandem
promis
antivir
therapi
must
identifi
within
next
sever
month
howev
number
clinic
trial
perform
timefram
limit
therefor
develop
mathemat
model
allow
project
possibl
therapeut
approach
model
recapitul
offtreat
viral
dynam
predict
threephas
immun
respons
addit
treatment
remdesivir
hydroxychloroquin
neutral
antibodi
cellular
immunotherapi
demonstr
vivo
drug
potenc
high
rapid
elimin
viru
possibl
potent
therapi
dose
soon
peak
viral
load
infect
peopl
typic
develop
symptom
predict
decreas
shed
durat
intens
effector
immun
respons
littl
effect
viral
area
curv
driven
high
level
earli
sar
replic
potent
therapi
dose
prior
peak
viral
load
infect
usual
presymptomat
predict
option
lower
viral
area
curv
also
identifi
clinic
meaning
drug
resist
less
like
emerg
highli
potent
agent
dose
peak
viral
load
result
support
earli
test
treat
approach
also
demonstr
need
identifi
earli
viral
shed
kinet
featur
predict
surrog
clinic
sever
transmiss
risk
pandem
devast
histor
event
current
impact
nearli
mankind
sar
incid
surg
numer
citi
countri
across
globe
infect
carri
high
mortal
rate
particularli
among
elderli
social
distanc
slow
even
elimin
mani
local
epidem
econom
viabl
longterm
strategi
evid
widespread
herd
immun
vaccin
unlik
develop
implement
within
next
month
therefor
second
third
wave
infect
like
occur
next
two
year
imper
optim
treatment
strategi
identifi
first
wave
infect
ensur
case
fatal
rate
lower
subsequ
local
epidem
date
select
antivir
agent
empir
guid
limit
absent
data
window
conduct
definit
clinic
trial
like
narrow
given
flatten
curv
effort
predict
slow
local
epidem
albeit
temporarili
therefor
effect
tool
urgent
need
optim
design
trial
use
mathemat
model
project
possibl
impact
two
small
molecular
agent
remdesivir
hydroxychloroquin
well
broadli
neutral
antibodi
cellular
immunotherapi
goal
model
interpret
emerg
clinic
trial
data
turn
perfect
subsequ
trial
term
select
antivir
agent
time
therapi
dosag
treatment
durat
avoid
drug
resist
select
virolog
endpoint
overal
simul
support
initi
therapi
soon
symptom
develop
also
suggest
urgent
need
studi
identifi
virolog
surrog
sar
sever
use
four
dataset
sar
shed
absenc
effect
treatment
develop
valid
mathemat
model
data
includ
infect
peopl
singapor
germani
one
korea
franc
fig
notabl
sampl
techniqu
differ
across
studi
singapor
korea
franc
sampl
obtain
nasopharyng
swab
wherea
germani
viral
load
measur
directli
sputum
shed
notabl
earli
peak
follow
three
phase
viral
decay
includ
rapid
initi
declin
peak
slower
period
decay
variabl
length
follow
third
abrupt
elimin
low
level
remain
viru
note
captur
viral
peak
well
final
rapid
clearanc
phase
subset
studi
particip
one
exampl
substanti
transient
viral
reexpans
fig
develop
seri
ordinari
differenti
equat
fit
viral
load
data
fig
method
materi
equat
captur
coupl
interact
suscept
cell
infect
cell
sar
mount
immun
respons
keep
standard
viral
dynam
model
viru
enter
suscept
cell
convert
infect
dell
produc
viru
fix
rate
base
model
fit
includ
two
immun
respons
first
account
rate
infect
cell
elimin
innat
immun
system
govern
expon
keep
prior
research
refer
densitydepend
immun
respons
second
phase
slower
cytolyt
respons
per
cell
kill
rate
satur
total
number
effector
cell
exce
certain
level
model
stage
presum
effector
cell
precursor
differenti
rate
q
method
calibr
time
model
reproduc
viral
load
kinet
particip
fig
certain
case
model
fit
avail
data
later
stage
shed
wherea
recapitul
entireti
viral
expans
peak
deceler
clearanc
sever
studi
particip
keep
observ
recent
clinic
trial
low
level
shed
continu
past
day
german
particip
wherea
viral
elimin
occur
remain
infect
peopl
continu
quantifi
valu
immun
term
particip
per
cell
kill
rate
total
number
cell
kill
per
day
extrem
high
first
sever
day
infect
particip
fig
b
coincid
peak
viral
load
cytolyt
immun
respons
initi
variou
timepoint
across
particip
day
led
lower
per
cell
total
kill
rate
rel
innat
respons
suffici
elimin
remain
infect
fig
develop
pharmacokinet
pharmacodynam
model
remdesivir
fig
broadspectrum
nucleotid
analogu
target
sar
replic
infect
cell
model
link
intraven
administr
plasma
level
free
drug
concentr
drug
activ
nucleotidetriphosph
compon
ntp
observ
within
pbmc
nonhuman
primat
captur
slow
decay
ntp
within
compart
fig
multipl
dose
project
stabl
level
ntp
target
cell
time
fig
follow
slow
decay
cessat
treatment
next
simul
possibl
dose
respons
curv
antivir
efficaci
captur
percentag
viral
replic
elimin
accord
micromolar
concentr
drug
percent
viral
replic
suppress
given
intracellular
drug
concentr
depend
intracellular
drug
concentr
drug
requir
lower
viral
replic
fig
note
intracellular
unknown
remdesivir
particularli
vivo
make
predict
clinic
trial
outcom
imposs
final
combin
pk
pd
model
fig
project
percentag
viral
replic
inhibit
time
differ
assum
intracellular
valu
high
assum
drug
potenc
um
antivir
effect
sustain
dose
interv
maintain
long
period
drug
deliveri
stop
fig
higher
assum
valu
remdesivir
potenc
project
lower
next
simul
therapi
day
infect
fig
sever
infect
peopl
often
seek
hospit
care
day
infect
immedi
viral
peak
fig
infect
peopl
often
becom
symptomat
case
remdesivir
vivo
potenc
assum
high
um
viral
elimin
occur
rapidli
initi
therapi
effect
occur
unoppos
remov
approxim
infect
cell
per
day
ongo
innat
immun
respons
fig
simul
assumpt
less
potent
version
remdesivir
um
result
lower
viral
clearanc
slope
result
impli
viral
clearanc
slope
clinic
trial
use
concert
model
directli
estim
vivo
intracellular
valu
remdesivir
treat
patient
model
use
project
effect
increas
decreas
dose
subsequ
trial
next
perform
simul
therapi
earli
timepoint
infect
prior
peak
viral
load
infect
peopl
presymptomat
stage
model
realiz
may
close
reflect
implement
post
exposur
prophylaxi
strategi
peopl
alreadi
earli
stage
infect
time
first
dose
scenario
extrem
potent
um
therapi
day
infect
result
immedi
viral
suppress
fig
earli
low
moder
potenc
treatment
model
predict
therapeut
failur
persist
sar
shed
due
insuffici
earli
immun
viru
fig
next
repeat
exercis
shorter
cours
treatment
result
similar
though
simul
assumpt
extrem
earli
initi
therapi
lead
full
sar
suppress
within
timefram
fig
next
assess
unknown
variabl
therapeut
model
predict
relev
therapeut
outcom
independ
variabl
select
vivo
intracellular
potenc
remdesivir
sar
human
unknown
infect
durat
time
treatment
initi
depend
variabl
select
shed
durat
viral
area
curv
unclear
outcom
stronger
predictor
progress
cytokin
storm
respiratori
failur
well
transmiss
infect
peopl
also
includ
final
talli
effector
cell
outcom
may
also
predict
likelihood
cytokin
storm
earli
initi
highli
potent
therapi
predict
lower
shed
durat
whether
given
prepeak
asymptomat
phase
postpeak
symptomat
phase
beyond
day
infect
howev
extrem
earli
initi
lower
potenc
therapi
predict
prolong
shed
rel
treatment
fig
high
drug
potenc
extrem
earli
treatment
initi
presymptomat
stage
infect
requir
significantli
lower
viral
area
curv
even
highli
potent
therapi
earliest
symptomat
phase
day
slight
impact
viral
area
curv
reflect
fact
viru
infect
cell
gener
first
day
sar
infect
fig
final
initi
highli
potent
therapi
within
day
infect
lower
extent
effector
cell
respons
simul
fig
may
suggest
earli
test
treat
strategi
could
lower
deleteri
infect
associ
inflamm
base
mutat
rate
posit
ss
rna
virus
approxim
mutat
per
base
pair
per
cell
infect
fact
two
separ
mutat
may
induc
partial
remdesivir
resist
sar
turn
lead
less
fit
viru
estim
probabl
drug
resist
mutant
would
emerg
therapi
assum
potent
therapi
model
project
singl
doubl
mutant
emerg
unlik
predomin
meaning
extend
durat
shed
dose
symptomat
phase
diseas
though
resist
may
emerg
earli
dose
fig
b
howev
moder
potenc
assum
singl
mutant
resist
predict
persist
particularli
therapi
initi
viral
peak
fig
b
assum
singl
point
mutat
sar
could
theoret
induc
complet
resist
treatment
failur
may
occur
regardless
dose
time
resist
strain
predict
predomin
rais
possibl
transmit
drug
resist
fig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
use
multicompart
pkpd
model
hydroxychloroquin
fig
first
recapitul
drug
level
drug
time
follow
singl
dose
fig
simul
twice
daili
dose
day
fig
gener
theoret
dose
respons
curv
fig
project
drug
efficaci
time
fig
remdesivir
predict
efficaci
therapi
shed
depend
time
treatment
intracellular
vivo
fig
lower
area
curv
requir
extrem
earli
initi
potent
treatment
fig
decreas
number
effector
cell
requir
effect
dose
within
first
day
infect
fig
broadli
neutral
antibodi
predict
next
simul
singl
infus
broadli
neutral
antibodi
prolong
halflif
broadli
neutral
antibodi
design
stop
infect
new
cell
rather
elimin
viral
replic
use
dual
compart
pk
model
fig
estim
antibodi
level
time
follow
singl
dose
fig
gener
theoret
dose
respons
curv
fig
project
antibodi
efficaci
time
fig
predict
efficaci
therapi
shed
depend
time
treatment
vivo
fig
lower
durat
shed
number
effector
cell
depend
therapeut
potenc
effect
lower
viral
area
curv
requir
extrem
earli
initi
potent
treatment
fig
gener
potenti
effect
cellular
immunotherapi
would
presum
decreas
lifespan
infect
cell
project
intervent
would
need
increas
rate
match
efficaci
potent
small
molecular
agent
fig
immunotherapi
project
efficaci
start
prior
peak
shed
fig
sar
infect
character
stereotyp
viral
kinet
pattern
high
peak
viral
load
first
sever
day
infect
subsequ
short
rapid
decay
period
follow
slower
clearanc
phase
variabl
durat
final
rapid
elimin
phase
mathemat
model
reproduc
data
explain
transit
first
second
phase
viral
decay
govern
densiti
depend
term
massiv
die
infect
cell
occur
peak
viremia
viral
clearanc
rate
slow
consider
viral
load
decreas
threshold
rna
copi
late
slowli
expand
cytolyt
cell
respons
predict
induc
erad
infect
cell
upper
airway
day
later
time
final
respons
appear
variabl
among
infect
peopl
moreov
unknown
cessat
viral
replic
nasopharynx
guarante
result
lung
anatom
compart
built
therapi
simul
top
natur
kinet
glean
knowledg
possibl
impact
antivir
therapi
accur
predict
imposs
absenc
clinic
trial
data
abl
make
sever
observ
highlight
import
treatment
viral
dynam
understand
treatment
effect
result
guid
futur
studi
design
assist
interpret
forthcom
trial
data
multipl
way
first
critic
know
whether
vitro
potenc
assess
remdesivir
hydroxycholorquin
bnab
project
onto
human
infect
previous
demonstr
vivo
valu
antivir
agent
exceed
estim
deriv
cell
cultur
experi
multipl
small
molecul
antivir
drug
similar
observ
hypothes
hiv
target
monoclon
neutral
antibodi
unclear
discrep
occur
due
low
blood
level
tissu
differ
cell
metabol
drug
tissu
higher
protein
bind
vivo
whatev
case
vitro
potenc
measur
hydroxycholoroquin
remdesivir
overestim
vivo
activ
higher
intracellular
level
requir
plasma
drug
may
less
effect
clinic
trial
higher
dose
may
possibl
solut
circumv
issu
second
effect
dose
symptom
develop
predict
rapid
subsequ
elimin
infect
current
clinic
trial
focus
primarili
hospit
patient
wherea
result
covid
model
suggest
treatment
day
immedi
follow
symptom
onset
decreas
durat
detect
viral
shed
model
also
predict
earli
treatment
limit
extent
cytolyt
immun
respons
requir
clear
infect
either
outcom
correl
progress
sever
diseas
transmiss
risk
hiv
influenza
ebola
earli
test
treat
vital
current
overlook
strategi
third
effect
dose
soon
onset
symptom
predict
insignific
effect
viral
load
auc
phenomenon
occur
amount
viru
produc
per
hour
earli
peak
far
higher
amount
produc
per
day
lower
viral
load
second
decay
phase
find
provid
cautionari
messag
subsequ
diseas
sever
develop
imprint
high
viral
load
presymptomat
phase
infect
earli
antivir
therapi
could
theoret
elimin
shed
without
alter
clinic
outcom
moreov
extrem
high
viral
load
period
respons
transmiss
suggest
gener
time
infect
earli
elimin
shed
may
lower
transmiss
either
overal
result
highlight
urgent
need
studi
identifi
earli
viral
immun
correl
sever
diseas
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
transmiss
inde
preliminari
studi
suggest
present
viral
load
may
impact
diseas
sever
fourth
therapi
initi
presymptomat
stage
infect
may
occur
post
exposur
prophylaxi
effect
predic
high
potenc
subtherapeut
small
molecular
agent
may
fact
prolong
infect
base
result
suggest
sampl
late
timepoint
post
exposur
prophylaxi
trial
fifth
approach
suggest
develop
lowlevel
drug
resist
occur
commonli
treatment
remdesivir
unlik
predispos
treatment
failur
provid
drug
potent
predomin
suscept
strain
resist
variant
like
present
low
level
rel
suscept
strain
make
transmiss
resist
far
less
like
import
except
may
occur
immunocompromis
host
might
shed
respiratori
virus
longer
higher
level
therebi
increas
chanc
de
novo
resist
context
moder
potent
antivir
therapi
final
model
project
high
likelihood
success
neutral
antibodi
cellular
immunotherapi
provid
achiev
adequ
potenc
dose
earli
summari
model
provid
broad
platform
assess
major
type
therapi
result
demonstr
need
differenti
whether
durat
viral
shed
viral
area
curv
relev
surrog
sever
viral
area
curv
predict
poor
outcom
form
antivir
therapi
outsid
potent
post
exposur
prophylaxi
unlik
provid
clinic
benefit
howev
shed
durat
best
surrog
earli
test
treat
approach
highli
promis
limit
likelihood
sever
diseas
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
employ
ordinari
differenti
equat
model
analyz
inhost
sar
dynam
infect
individu
potenti
vivo
effect
differ
treatment
strategi
first
fit
model
viral
load
data
differ
sourc
use
nonlinearmix
effect
approach
second
use
pharmacokinet
model
fit
observ
plasma
concentr
remdesivir
rdv
activ
nucleosid
triphosph
form
pbmc
blood
concentr
hydroxychloroquin
hcq
third
simul
dose
respons
curv
antivir
effect
rdv
hcq
use
differ
possibl
half
maxim
effect
concentr
base
invitro
estim
fourth
simul
therapi
differ
time
infect
analyz
potenti
reduct
sar
shed
final
repeat
project
therapi
includ
emerg
resist
therapi
analyz
viral
load
data
patient
infect
sar
monitor
receiv
support
therapi
hospit
singapor
germani
south
korea
franc
patient
less
data
point
oscillatori
viral
dynam
exclud
first
data
set
obtain
sar
patient
follow
hospit
singapor
januari
rd
februari
rd
patient
diagnos
state
travel
wuhan
china
last
two
week
enrol
viral
load
observ
obtain
differ
specimen
blood
stool
urin
sampl
analyz
come
nasopharyng
swab
cycl
threshold
obtain
revers
transcriptas
polymeras
chain
reaction
rtpcr
multipl
time
first
week
enrol
second
data
set
obtain
infect
patient
enrol
treat
singl
hospit
munich
germani
januari
rd
januari
th
patient
infect
report
happen
contact
index
case
viral
load
observ
obtain
daili
sputum
pharyng
swab
stool
use
rtpcr
analyz
viral
rna
concentr
sputum
third
data
set
come
first
sar
infect
case
korea
chines
citizen
come
wuhan
china
nasopharyng
swab
viral
load
obtain
daili
day
symptom
onset
use
rtpcr
fourth
data
set
came
four
patient
admit
hospit
pari
bordeaux
franc
viral
load
obtain
nasopharyng
swab
use
rtpcr
analyz
viral
load
data
digit
publish
studi
viral
load
observ
publish
cycl
threshold
ct
valu
convert
copi
per
swab
use
relat
valu
assum
lower
limit
detect
copi
per
sampl
pk
data
hcq
specif
mg
oral
dose
gather
pk
data
rdv
gather
nonhuman
primat
nhp
intraven
receiv
rdv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
dose
day
plasma
concentr
rdv
activ
nucleosid
triphosph
form
pbmc
record
hour
digit
data
employ
fit
pk
model
rdv
understand
observ
shed
dynam
develop
viral
infect
model
modifi
previou
model
viru
dynam
model
suscept
cell
infect
rate
v
cell
clear
two
way
innat
respons
densiti
depend
rate
acquir
respons
rate
mediat
effector
cell
expon
describ
much
first
death
rate
depend
infect
cell
densiti
hill
coeffici
parameter
nonlinear
second
respons
allow
rapid
satur
kill
paramet
defin
effector
cell
level
kill
infect
cell
half
maxim
produc
rate
clear
rate
model
effector
cell
rise
stage
precursor
cell
first
precursor
cell
compart
prolifer
presenc
infect
rate
differenti
effector
cell
per
capita
rate
intermedi
stage
final
effector
cell
die
rate
best
instanc
model
express
schemat
fig
system
ordinari
differenti
equat
fit
differ
instanc
model
equat
shed
data
use
nonlinear
mixedeffect
model
approach
see
tabl
briefli
obtain
maximum
likelihood
estim
popul
median
fix
effect
standard
deviat
random
effect
model
paramet
use
stochast
approxim
expect
maxim
saem
algorithm
embed
monolix
softwar
wwwlixofteu
subset
paramet
random
effect
specifi
standard
deviat
valu
estim
measur
error
varianc
also
estim
assum
addit
error
model
log
simultan
fit
model
viral
load
data
patient
form
four
data
set
paramet
associ
effector
cell
compart
estim
studi
particip
clear
infect
observ
data
model
fit
assum
time
first
posit
viral
load
person
howev
defin
initi
valu
time
infect
ie
cell
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
sinc
infect
start
first
detect
viral
load
fix
initi
valu
cell
cell
fix
paramet
day
day
cell
assum
valu
low
percentag
activ
cell
start
grow
moment
viral
load
drop
estim
remain
paramet
includ
time
infect
determin
parsimoni
model
among
instanc
avail
sar
shed
data
comput
loglikelihood
log
l
akaik
inform
criteria
number
paramet
estim
assum
model
similar
support
data
differ
aic
best
model
lowest
aic
less
two
reproduc
pk
data
rdv
employ
simpl
two
compart
model
first
compart
repres
amount
rdv
plasma
volum
second
compart
denot
amount
activ
nucleosid
triphosph
form
pbmc
volum
assum
rdv
get
metabol
activ
nucleosid
triphosph
form
rate
wherea
rdv
activ
nucleosid
triphosph
form
elimin
respect
compart
rate
respect
model
given
drug
concentr
record
convert
amount
drug
given
mg
divid
convers
factor
respect
combin
volum
distribut
two
compart
molar
mass
two
form
rdv
fit
model
pk
data
nhp
use
nonlinear
least
squar
approach
use
initi
dose
adapt
dose
human
assum
normal
weight
recapitul
pharmacokinet
hcq
develop
model
pharmacokinet
model
chloroquin
cq
hcq
deriv
cq
activ
metabolit
fourcompart
model
drug
get
absorb
gut
compart
rate
enter
central
compart
volum
elimin
rate
rate
constant
repres
movement
drug
central
compart
first
peripher
compart
volum
first
peripher
compart
volum
respect
similarli
movement
drug
compart
central
compart
model
use
respect
model
equat
repres
amount
drug
compart
given
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
fit
model
pk
data
use
nonlinear
least
squar
approach
pharmacokinet
intraven
inject
broadli
neutral
antibodi
bnab
simul
use
simpl
biphas
exponenti
model
model
ad
repres
distribut
clearanc
rate
bnab
wherea
describ
coeffici
associ
fix
paramet
ml
ml
day
follow
estim
bnab
also
fix
thu
antivir
effect
intracellular
hcq
calcul
use
valu
estim
vitro
sar
hydroxychloroquin
remdesivir
hypothet
vivo
valu
time
vitro
valu
also
explor
antivir
effect
hypothet
bnab
use
form
vari
valu
final
model
potenti
antivir
effect
immunotherapi
enhanc
earli
death
rate
infect
cell
factor
adapt
model
equat
allow
emerg
resist
rdv
base
modif
fact
two
separ
mutat
may
induc
partial
resist
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
rdv
sar
turn
lead
less
fit
viru
case
sar
two
singl
mutat
induc
less
sensit
viru
increas
rdv
combin
mutat
emerg
mediat
increas
rdv
includ
find
model
assum
infect
cell
h
produc
sensit
viru
h
transit
infect
cell
produc
less
sensit
viru
due
one
mutat
viral
replic
cycl
two
viral
popul
increas
higher
similarli
assum
transit
infect
cell
produc
resist
strain
higher
anoth
mutat
also
allow
revers
mutat
event
assum
mutat
probabl
per
infect
event
assumpt
total
viral
load
defin
h
total
number
infect
cell
h
modif
model
becom
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
first
symptom
day
first
posit
sampl
c
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
overal
earli
potent
treatment
limit
durat
infect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
heatmap
compar
varianc
drug
potenc
measur
vivo
xaxi
time
treatment
initi
yaxi
shed
durat
b
viral
load
area
curv
auc
c
extent
cell
respons
requir
viral
elimin
potent
therapi
within
first
day
infect
limit
shed
durat
extent
cell
respons
howev
extrem
earli
therapi
presymptomat
phase
infect
lower
viral
auc
subpot
therapi
given
extrem
earli
presymptomat
stage
may
extend
shed
durat
lower
viral
load
limit
effector
cell
respons
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
project
remdesivir
drug
resist
therapi
simul
high
potenc
um
assumpt
mutant
confer
partial
drug
resist
treatment
initi
timepoint
gener
consist
hospit
day
first
posit
sampl
first
symptom
day
first
posit
sampl
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
project
treatment
treatment
assum
drug
resist
treatment
assum
drug
resist
b
project
assum
drug
resist
trajectori
sensit
strain
singl
mutant
doubl
mutant
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
project
remdesivir
drug
resist
therapi
simul
moder
potenc
um
assumpt
mutant
confer
partial
drug
resist
treatment
initi
timepoint
gener
consist
hospit
day
first
posit
sampl
first
symptom
day
first
posit
sampl
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
project
treatment
treatment
assum
drug
resist
treatment
assum
drug
resist
b
project
assum
drug
resist
trajectori
sensit
strain
singl
mutant
doubl
mutant
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
fig
project
remdesivir
drug
resist
therapi
simul
high
potenc
um
assumpt
mutant
confer
complet
drug
resist
treatment
initi
timepoint
gener
consist
hospit
day
first
posit
sampl
first
symptom
day
first
posit
sampl
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
project
treatment
treatment
assum
drug
resist
treatment
assum
drug
resist
b
project
assum
drug
resist
trajectori
sensit
strain
singl
mutant
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
fig
treatment
project
hydroxychloroquin
assum
differ
potenc
time
treatment
set
simul
perform
assumpt
high
medium
low
potenc
treatment
initi
timepoint
gener
consist
hospit
day
first
posit
sampl
b
first
symptom
day
first
posit
sampl
c
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
overal
earli
potent
treatment
limit
durat
infect
heatmap
compar
varianc
drug
potenc
measur
vivo
xaxi
time
treatment
initi
yaxi
e
shed
durat
f
viral
load
area
curv
auc
g
extent
cell
respons
requir
viral
elimin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
set
simul
perform
assumpt
high
medium
low
potenc
treatment
initi
timepoint
gener
consist
hospit
day
first
posit
sampl
b
first
symptom
day
first
posit
sampl
c
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
overal
earli
potent
treatment
limit
durat
infect
heatmap
compar
varianc
bnab
potenc
measur
vivo
xaxi
time
treatment
initi
yaxi
e
shed
durat
f
viral
load
area
curv
auc
g
extent
cell
respons
requir
viral
elimin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
fig
treatment
project
cytolyt
immunotherapi
assum
differ
potenc
time
treatment
set
simul
perform
assumpt
high
medium
low
potenc
base
multipl
effect
infect
cell
death
rate
treatment
initi
timepoint
gener
consist
hospit
day
first
posit
sampl
b
first
symptom
day
first
posit
sampl
c
presymptomat
postpeak
phase
day
first
posit
sampl
presymptomat
prepeak
phase
day
overal
earli
potent
treatment
limit
durat
infect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
tabl
akaik
inform
criterion
aic
multipl
instanc
model
differ
number
compart
hillcoeffici
associ
effector
cell
respons
lower
aic
better
support
combin
paramet
model
found
best
support
data
bold
red
comprehens
also
tri
model
ie
effector
cell
respons
model
case
found
support
choic
model
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
